Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
about
New Insights into the Generation of CD4 Memory May Shape Future Vaccine Strategies for InfluenzaInfluenza Burden and Transmission in the TropicsSafety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trialsReplication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates.New vaccines against influenza virus.Induction of long-term protective immune responses by influenza H5N1 virus-like particles.Influenza vaccines based on virus-like particlesCurrent status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.Rapid influenza A testing for novel H1N1: point-of-care performance.Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic VirusModifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses.Novel vaccines against influenza viruses.Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokinesDevelopment of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine.Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children.Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children.Intranasal Immunization of Mice to Avoid Interference of Maternal Antibody against H5N1 Infection.Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected childrenEfficacy of live attenuated influenza vaccine in children 6 months to 17 years of age.Blocking interhost transmission of influenza virus by vaccination in the guinea pig model.Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings.Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice.The intranasal adjuvant Endocine™ enhances both systemic and mucosal immune responses in aged mice immunized with influenza antigen.Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.When Do Coughs and Sneezes Cause Diseases?Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine.Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis.It ain't necessarily so: a surprising lower airway infection.Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections.Development of Endotoxin Tolerance Does Not Influence the Response to a Challenge with the Mucosal Live-Attenuated Influenza Vaccine in Humans In Vivo.Immune responses after live attenuated influenza vaccination.
P2860
Q26752546-4E53860B-8D36-4DAE-90BF-8DA4EC57F492Q28085254-29AE74B7-965F-40C7-A20B-53AC378033DEQ28748654-82BE86ED-C710-4B4E-BA13-B92616BB555EQ30206089-33BF535D-313F-4CE6-86CF-B0FDAA58624CQ30357932-D2F001BE-0F10-4EF5-8201-C5CBA139A549Q30375255-CD915570-5392-4DB8-81F4-565050F8E25AQ30376236-6102D50A-A74A-4CBD-8FB8-E28BDC7245B8Q30377205-AEFD67D2-9EB7-43AC-B79C-09A282B81427Q30384941-DC3909D5-0294-4AFC-B0F2-FD319791B016Q30390811-BADEDED1-F281-41A9-A214-18F14496A708Q30395088-4E0C5826-9735-4542-9C67-7141E5F174BEQ30407716-500F093F-044B-404C-BC62-E6FE33B40EC9Q30420603-A77D3D60-2975-4FD3-8429-969C355EB17DQ33687181-DA4D2D8E-D5D5-43AF-B68F-B3646510DD47Q34390072-58661828-C963-4673-A77B-D12DFF21F336Q34458066-9FABBBDF-07A6-4BB6-A753-81ECD78D372DQ35110968-751B3B26-F9B9-4337-A807-D732D9B4E094Q35531941-3E46F5B5-9105-44F5-8A9C-26A3F30D3BC2Q35789909-BB775378-3E30-449E-A476-6F3E11188AD8Q36046358-AB98C78C-A7F9-411A-92AE-62E2C4B3E3B7Q37040671-1CC727CD-87B6-414D-8980-13FD88C21470Q37087100-86CB06F4-57F2-422E-8E76-1821BD731BFDQ37127910-4381365C-F291-462B-820A-BC9A83B3B874Q37338060-302AFB81-1958-4FB1-8C0D-EF263BD6C139Q37621640-164E97BE-F823-4C5C-A76D-27E0E8FD42D7Q37679085-46809A49-0534-40EF-B405-C6A7A9BD27F8Q37921281-E4CBEED2-1A3E-44DC-ADD1-CF47A093C34CQ38059737-786FE0E3-2188-49D0-880B-ACDCC373DB47Q39029228-BA21780F-622E-4C70-9D82-A18C8E6007BCQ40131850-CD88109F-7CC2-4EB7-8538-E17024031DA6Q40302595-0A3679F7-B48F-49FB-81F2-8C6CF6EF7BBFQ40472924-5E20AC22-9AD3-46A4-A60E-9BB20A70FD99Q47281607-5E0B49A8-EA93-4965-91BD-DF7CA93D3D19Q47556941-BC6004EB-E4EE-4E23-B89D-C8D6D361D972Q47937377-574B568F-BBD2-4328-8D8C-67B754E53277
P2860
Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@ast
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@en
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@nl
type
label
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@ast
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@en
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@nl
prefLabel
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@ast
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@en
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@nl
P2093
P1433
P1476
Shedding and immunogenicity of ...... in subjects 5-49 years of age.
@en
P2093
Robert E Walker
Stan L Block
P304
P356
10.1016/J.VACCINE.2008.07.013
P407
P577
2008-07-26T00:00:00Z